Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project some revenue, and look to the pace. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -3.12% in last session and finished the day at $6.22. Traded volume was 6.73million shares in the last session and the average volume of the stock remained 6.12million shares. The beta of the stock remained -0.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was one of the biggest losers today, as it fell by 27%. While certainly not an upward momentum stock at this point, as shares have been declining over the last three months, the company had bad news today. Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped -27.26 percent to $8.43 Friday on volume of 20.01million shares. The intra-day range of the stock was $7.88 to $9.20. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $1.03billion.

Gildan Activewear Inc. (USA) (NYSE:GIL) announced that Laurence G. Sellyn, Executive Vice-President, Chief Financial and Administrative Officer, will present an overview of the Company’s growth strategies at the 2014 CIBC Retail and Consumer Conference in Toronto, Ontario, on Wednesday, March 26, 2014, at 9:15 AM ET. Gildan Activewear Inc (USA) (NYSE:GIL)’s stock on Apr 04, 2014 reported a decrease of -0.35% to the closing price of $51.12. Its fifty two weeks range is $38.11-$55.00. The total market capitalization recorded $6.24billion. The overall volume in the last trading session was 303,401.00million shares. In its share capital, GIL has 122.16million outstanding shares.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) CMO Frank Haluska unloaded 3,400 shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $8.21, for a total value of $27,914.00. On Friday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -2.45% to close the day at $7.58. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -9.44%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is 6.01%.